Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05458427 | Dedicated Breast CT for Diagnosis of Breast Cancer | — | terminated | Jul 14, 2022 | Radboud University Medical Center | Unethical to include many more patients when currently obtained results are sufficient. | Other (stated, no rule matched) |
| NCT05474690 | A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of… | Phase 3 | withdrawn | Jul 26, 2022 | Henan Cancer Hospital | The new treatment plan for HER2 positive breast cancer has entered the diagnosis and treatment… | Other (stated, no rule matched) |
| NCT04927481 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2… | Phase 2 | terminated | Jun 16, 2021 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT04995575 | Dissecting the Pathways of Therapy Resistance in Early Breast Cancer(MINDACTRelapse) | — | terminated | Aug 9, 2021 | European Organisation for Research and Treatment of Cancer - EORTC | Closed as not feasible | Other (stated, no rule matched) |
| NCT05263648 | Virtual Reality Software to Reduce Stress in Cancer Patients(OU-SCC VR) | N/A | withdrawn | Mar 2, 2022 | University of Oklahoma | due to an issue with the software developer that cannot be resolved. | Other (stated, no rule matched) |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast…(TENACITY) | Phase 2 | terminated | Jul 8, 2020 | Ayala Pharmaceuticals, Inc, | Sponsor's decision | Sponsor / business decision |
| NCT05236387 | Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer… | — | terminated | Feb 11, 2022 | Johns Hopkins University | PI left institution | Investigator |
| NCT04156880 | Artificial Intelligence in Mammography-Based Breast Cancer Screening | — | withdrawn | Nov 8, 2019 | Chinese University of Hong Kong | the collaborating party of AI system withdraw their study due to change of company policy in year… | COVID-19 / pandemic |
| NCT00984490 | Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can… | N/A | terminated | Sep 25, 2009 | Vanderbilt-Ingram Cancer Center | slow accrual | Enrollment / accrual |
| NCT01956552 | Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and… | N/A | terminated | Oct 8, 2013 | Institut Curie | not stated | Not stated |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | Phase 1 / Phase 2 | terminated | May 11, 2016 | Cambridge University Hospitals NHS Foundation Trust | Slow recruitment | Enrollment / accrual |
| NCT04869943 | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic…(ARTEST) | Phase 3 | terminated | May 3, 2021 | Veru Inc. | Business decision | Sponsor / business decision |
| NCT05489679 | A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast… | Phase 1 | terminated | Aug 5, 2022 | Accutar Biotechnology Inc | Voluntarily terminate the study since the sponsor's development strategy was adjusted. | Sponsor / business decision |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT04947917 | Axillary Lymph Node Tattoo Marking Study | N/A | terminated | Jul 1, 2021 | Dana-Farber Cancer Institute | Institutional standard of care regarding axillary management changed. Decision was made to close… | Other (stated, no rule matched) |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT03981718 | Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in… | N/A | withdrawn | Jun 11, 2019 | Mayo Clinic | low/slow accrual | Enrollment / accrual |
| NCT05315687 | Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy | Phase 2 | withdrawn | Apr 7, 2022 | Emory University | Study is being closed because PI left Emory | Investigator |
| NCT03970967 | Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma… | N/A | terminated | Jun 3, 2019 | Alpha Tau Medical LTD. | Difficulty in recruiting patients | Enrollment / accrual |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT02823262 | A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older | N/A | terminated | Jul 6, 2016 | Beth Israel Deaconess Medical Center | Did not receive funding for the trial. | Funding |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug… | Phase 1 / Phase 2 | terminated | May 11, 2017 | CytomX Therapeutics | Covid Pandemic; Business Decision to separate Phase 2 to new study | COVID-19 / pandemic |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04756505 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Feb 16, 2021 | M.D. Anderson Cancer Center | Per Sponsor Request-no longer manufacturing the study drug | Drug supply |
| NCT03480659 | Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of… | — | terminated | Mar 29, 2018 | HKGepitherapeutics | Experienced technical issues with plasma blood samples collected from patients. | Other (stated, no rule matched) |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in… | Early Phase 1 | withdrawn | Jul 20, 2022 | Mainline Biosciences, Inc. | The study was terminated due to Sponsor decision | Sponsor / business decision |
| NCT04714619 | CB-103 Plus NSAI In Luminal Advanced Breast Cancer(CAILA) | Phase 2 | terminated | Jan 19, 2021 | MedSIR | Sponsor decision | Sponsor / business decision |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT00679029 | Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2… | Phase 2 | terminated | May 16, 2008 | University of Nebraska | drug toxicity | Safety / toxicity |
| NCT06161792 | Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer(VMS) | Phase 2 | terminated | Dec 8, 2023 | Yung Shin Pharm. Ind. Co., Ltd. | Difficulty in recruiting breast cancer patients, leading to a slow rate of case enrollment. | Enrollment / accrual |
| NCT02642094 | Aging Mammary Stem Cells and Breast Cancer Prevention | Phase 2 | terminated | Dec 30, 2015 | LuZhe Sun | The study was terminated early according to the protocol due to efficacy. | Efficacy / futility |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative…(TARA) | Phase 2 | terminated | Dec 31, 2020 | Mylin A. Torres, MD | This study has been terminated due to Lack of Accrual. | Enrollment / accrual |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT02963363 | Adapted Physical Activity for Breast Cancer HER2 Positive Patient(APACAN2) | N/A | terminated | Nov 15, 2016 | Centre Jean Perrin | Insufficient recruitment | Enrollment / accrual |
| NCT01990352 | Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy | Phase 2 | terminated | Nov 21, 2013 | University of Arizona | The PI determined that study specimens being obtained did not yield sufficient data to analyze the… | Enrollment / accrual |
| NCT01931709 | FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer | N/A | terminated | Aug 29, 2013 | University of Washington | Terminated due to end of funding | Funding |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT02127073 | Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women… | Phase 2 | terminated | Apr 30, 2014 | Montefiore Medical Center | Could not identify collaborator and secure additional funding after transferring the record to… | Funding |
| NCT04149522 | Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation… | Phase 2 | terminated | Nov 4, 2019 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | The mepitel film was expired and was no longer available. | Other (stated, no rule matched) |
| NCT05905341 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in… | Phase 1 | withdrawn | Jun 15, 2023 | Pfizer | This decision was based on business considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT03931655 | Photoacoustic Lymph Node Imaging | — | terminated | Apr 30, 2019 | Geoff Luke | There have been multiple issues getting the device repaired and then in working order. The PI's… | Other (stated, no rule matched) |
| NCT05301595 | TAP vs QL for Postoperative Analgesia After DIEP Free Flap Breast Reconstruction | N/A | withdrawn | Mar 29, 2022 | Ottawa Hospital Research Institute | Study was never started as PI moved to another city | Other (stated, no rule matched) |
| NCT04932031 | Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy(SENSE) | — | terminated | Jun 18, 2021 | Sapere Bio | under enrollment for primary endpoint analysis | Enrollment / accrual |
| NCT04054752 | Vaccine Response With NT-I7 | Phase 1 | withdrawn | Aug 13, 2019 | National Cancer Institute (NCI) | No subjects enrolled. | Enrollment / accrual |
| NCT03786094 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer(FORTRESS) | Phase 3 | terminated | Dec 24, 2018 | Spexis AG | The study was halted early due to failure to meet the primary endpoint. | Other (stated, no rule matched) |
| NCT00019643 | Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer | — | terminated | Mar 6, 2007 | National Institutes of Health Clinical Center (CC) | not stated | Not stated |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté(ICE) | N/A | terminated | Dec 10, 2015 | Centre Hospitalier Universitaire de Besancon | inclusions problems | Other (stated, no rule matched) |
| NCT05436808 | Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer | Early Phase 1 | withdrawn | Jun 29, 2022 | Stony Brook University | No eligible participants identified | Other (stated, no rule matched) |
| NCT03623490 | Optimizing the Management of Patients With Oral Therapy(IPAC) | N/A | terminated | Aug 9, 2018 | Centre Georges Francois Leclerc | Following an insufficient recruitment, the sponsor decided to halt prematurely inclusions | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 26, 2024source: clinicaltrials